Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 16/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.62 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4099316 | 1.00 | GRIA2 (1.00) | GRIA2KCNH2GRIA4SLC6A4SLC6A3 | |
| SCHEMBL4099320 | 1.00 | GRIA2 (1.00) | GRIA2KCNH2GRIA4SLC6A4SLC6A3 | |
| SCHEMBL13140776 | 0.86 | GRIA2 (0.75) | GRIA2KCNH2GRIA4SLC6A4SLC6A3 | |
| SCHEMBL4957451 | 0.82 | GRIA2 (1.00) | GRIA2KCNH2 | |
| SCHEMBL1871135 | 0.81 | GRIA2 (0.69) | GRIA2KCNH2SLC6A4SLC6A3 | |
| SCHEMBL1871133 | 0.81 | GRIA2 (0.69) | GRIA2KCNH2SLC6A4SLC6A3 | |
| SCHEMBL1871132 | 0.81 | GRIA2 (0.69) | GRIA2KCNH2SLC6A4SLC6A3 | |
| SCHEMBL4102241 | 0.81 | GRIA2 (1.00) | GRIA2KCNH2GRIA4 | |
| SCHEMBL4102250 | 0.81 | GRIA2 (1.00) | GRIA2KCNH2GRIA4 | |
| SCHEMBL4102245 | 0.81 | GRIA2 (1.00) | GRIA2KCNH2GRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221643-A1 | 4-PHENYL-3-(2-PROPYLSULFONYLAMINO) TETRAHYDROFURAN DERIVATIVES WHICH POTENTIATE GLUTAMATE RECEPTORS AND ARE USEFUL IN THE TREATMENT OF SCHIZOPHRENIA | GLAXO GROUP LIMITED (GB) | 2009-09-03 | — | — | US | claimed |
| US-20090221643-A1 | 4-PHENYL-3-(2-PROPYLSULFONYLAMINO) TETRAHYDROFURAN DERIVATIVES WHICH POTENTIATE GLUTAMATE RECEPTORS AND ARE USEFUL IN THE TREATMENT OF SCHIZOPHRENIA | GLAXO GROUP LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20080139472-A1 | UPREGULATING BDNF LEVELS TO MITIGATE MENTAL RETARDATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221643-A1 | 4-PHENYL-3-(2-PROPYLSULFONYLAMINO) TETRAHYDROFURAN DERIVATIVES WHICH POTENTIATE GLUTAMATE RECEPTORS AND ARE USEFUL IN THE TREATMENT OF SCHIZOPHRENIA | GRIN2C, GRIN1, OXER1 | GRIA2 27/4885KCNH2 1331/4885GRIA4 19/4885 |
| US-20080139472-A1 | UPREGULATING BDNF LEVELS TO MITIGATE MENTAL RETARDATION | BDNF, MECP2, NTRK2 | GRIA2 43/4885KCNH2 4187/4885GRIA4 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.